Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ukoniq (umbralisib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Rhizen, TG Therap

Drug class:

PI3Kδ inhibitor, Casein kinase I epsilon inhibitor

Related drugs:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	umbralisib + ublituximab-xiiy Sensitive: B - Late Trials umbralisib + ublituximab-xiiy Sensitive : B	umbralisib + ublituximab-xiiy Sensitive: B - Late Trials umbralisib + ublituximab-xiiy Sensitive : B
IL2 elevation	Mantle Cell Lymphoma	IL2 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D
IL6 elevation	Mantle Cell Lymphoma	IL6 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D
TNFA elevation	Mantle Cell Lymphoma	TNFA elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D
Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	umbralisib Resistant: D – Preclinical umbralisib Resistant : D	umbralisib Resistant: D – Preclinical umbralisib Resistant : D
ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	umbralisib Resistant: D – Preclinical umbralisib Resistant : D	umbralisib Resistant: D – Preclinical umbralisib Resistant : D